Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 159,766 shares at $33.40 ($5.3M) on 2025-05-20, disclosed to the SEC on 2025-05-20.
Scheduled sale ($5.3M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.84 | 32,854 | $1.1M | 20.8% |
| 2 | $33.32 | 25,756 | $858K | 16.1% |
| 3 | $33.32 | 25,756 | $858K | 16.1% |
| 4 | $33.75 | 400 | $14K | 0.3% |
| 5 | $33.40 | 75,000 | $2.5M | 46.9% |
| Total | $33.47 avg | 159,766 |
| $5.3M |
| 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |